Home La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
 

Keywords :   


La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome

2014-09-03 11:49:25| drugdiscoveryonline Home Page

La Jolla Pharmaceutical Company a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, recently announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure

Tags: company trial patient clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
07.11Ahlstroms Climate Targets Validated by SBTi
07.11Mativ Reports Third Quarter Results
07.11Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
More »